TheraCIM (nimotuzumab)

P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

Biomarker analysis identified PD-L1 expression, TP53 mutation status, and CD8+ T cell density as potential predictive markers. Therefore, neoadjuvant TNT shows promising anti-tumor activity and acceptable toxicity.

P2, N=170, Recruiting, Sichuan Cancer Hospital and Research Institute | Trial completion date: Sep 2023 --> Oct 2027 | Trial primary completion date: Sep 2023 --> Oct 2025

P2, N=70, Not yet recruiting, Sun Yat-sen University

P2, N=40, Not yet recruiting, Shanxi Cancer Hospital; Shanxi Cancer Hospital

P1/2, N=10, Recruiting, West China Hospital,Sichuan University; West China Hospital,Sichuan University

P=N/A, N=27, Recruiting, Bejing Tongren Hospital, Capital Medical Uniersity; Bejing Tongren Hospital, Capital Medical Uniersity

P1/2, N=10, Recruiting, West China Hospital | Not yet recruiting --> Recruiting

PET imaging using the non-overlapping anti-EGFR radioimmunoconjugate [89Zr]Zr-DFO-matuzumab before and after treatment of orthotopic CRC xenografts showed that 1/5 mice from the treatment group had complete remission while metastatic spread was prevented in the other mice (4/5). These results show that treatment with [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 is a potential therapeutic approach for KRAS mutant and BRAFV600E mutant metastatic CRC.

Medications like Nimotuzumab, Cetuximab, and Panitumumab target the Epidermal Growth Factor Receptor (EGFR), which EGF activates. HER2, activated by ligands, is the focus of drugs like Trastuzumab and Pertuzumab. The PD-1/PD-L1 and CTLA-4 pathways, as the immune checkpoints, which involve T cells, are targeted by medications like Ipilimumab...HIF1A-AS1, CRNDE-h, NEAT1, ZFAS1, and GAS5, along with IGFBP-2, have demonstrated significant CRC diagnostic capacity. Compared to CRC patients with low HIF1A-AS1 expression, individuals with high expression levels were linked to a worse 5-year survival rate.

P4, N=171, Active, not recruiting, Biotech Pharmaceutical Co., Ltd.

P2, N=246, Active, not recruiting, Sun Yat-sen University | Trial primary completion date: Dec 2022 --> Aug 2024

The ICER consistently well exceeded the willingness-to-pay (WTP) threshold and negative INHBs were observed across all patient subcategories with zero alteration recorded as cost-effective in the subgroup analyses. Nimotuzumab plus gemcitabine, relative to gemcitabine alone, is not a cost-effective first-line treatment among patients with K-Ras wild type LA or mPC at the current prices offered in China.

P=N/A, N=62, Recruiting, Gansu Wuwei Tumor Hospital

Question How can the response to nimotuzumab treatment in patients with locally advanced nasopharyngeal carcinoma be accurately predicted using non-invasive imaging methods? Findings A combined clinical and radiomic model using dynamic contrast-enhanced magnetic resonance imaging showed improved predictive performance for progression-free survival in patients treated with nimotuzumab. Clinical relevance The study provides evidence for using a combined clinical and radiomic approach, offering a non-invasive method to predict treatment response and guide personalized treatment strategies for patients with locally advanced nasopharyngeal carcinoma, potentially improving patient outcomes.

These include nimotuzumab (an anti-EGFR drug) and vinorelbine (a semisynthetic vinca alkaloid) in combination, Panobinostat (a histone deacetylase inhibitor), ONC201 (a drug that blocks the dopamine receptor D2 and inactivates Akt and ERK kinases), and chimeric antigen receptor (CAR) T cells. Because the H3K27M mutation is linked to higher malignancy, a slightly higher dose could be used for the second round of local irradiation. Additionally, irradiating the entire craniospinal axis could help control both local and leptomeningeal disease.

P1/2, N=31, Completed, Biotech Pharmaceutical Co., Ltd. | Phase classification: P2a --> P1/2

P=N/A, N=50, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

P2, N=114, Shandong Second Provincial General Hospital; Shandong Second Provincial General Hospital

P2, N=156, Not yet recruiting, Biotech Pharmaceutical Co., Ltd.

P1/2, N=10, Not yet recruiting, West China Hospital

P2, N=32, Not yet recruiting, Zhejiang University

P2, N=43, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

In agreement, the anticancer drugs targeting EGFR such as Nimotuzumab and tyrosine kinase inhibitors are markedly effective on COVID-19...These animal models also display postpubertal abnormality in soliloquy-like self-vocalization as well as in intercortical functional connectivity. Here, we discuss neuropsychiatric implication of coronavirus infection and its interaction with the EGFR system, by searching related literatures in PubMed database as of the end of 2023.

However, no significant changes were observed in the populations of NK cells, DC cells, and neutrophils. These findings offer new insights into the anticancer mechanisms of nimotuzumab and its underlying synergy in combined treatments with immunotherapy for HNSCC.

P2, N=35, Completed, Anhui Provincial Hospital | Recruiting --> Completed | Phase classification: P1/2 --> P2 | N=57 --> 35 | Trial completion date: Dec 2025 --> Mar 2024

P2, N=35, Completed, Anhui Provincial Hospital | Phase classification: P1/2 --> P2 | N=57 --> 35 | Trial completion date: Dec 2025 --> Mar 2024 | Recruiting --> Completed

In summary, although there is no significant statistical difference between neoadjuvant chemotherapy with nimotuzumab combined with APF and APF alone in the pathological remission rate of locally advanced oral squamous cell carcinoma, there is a trend indicating that nimotuzumab combined with APF is superior.

P2, N=0, Withdrawn, Sun Yat-sen University | N=37 --> 0 | Recruiting --> Withdrawn

P2, N=57, Recruiting, Zhejiang Provincial People's Hospital

P2, N=112, Recruiting, The First Affiliated Hospital of Zhengzhou University

According to these observations, NmAb enhances the effectiveness of CPT-11 in fighting cancer by stimulating cell death in the HeLa cells. Therefore, NmAb has the potential to improve the efficacy of CPT-11 as a future cervical cancer treatment in humans.

P2, N=20, Enrolling by invitation, The First Affiliated Hospital of Xiamen University

We used the combined chemotherapy of gemcitabine (1,000 mg/m2) + oxaliplatin (135 mg/m2) + nimotuzumab (400 mg). Then, the patients were treated with oral olaparide (600 mg/day) for one year, and survived without tumor progress for more than 1.5 years. These two cases achieved excellent effects of precise chemotherapy, which provided an important reference for the treatment of pancreatic cancer patients with wild KRAS and mutant BRCA.

P=N/A, N=980, Completed, Xiangya Hospital of Central South University; Xiangya Hospital of Central South University

P2, N=37, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: Oct 2020 --> Oct 2027 | Trial primary completion date: Oct 2018 --> Oct 2025

P3, N=354, Recruiting, Biotech Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

EGFR and PD-L1 are highly expressed in OSCC, the combination of which is important for a precise prognosis of OSCC. EGFR and PD-L1 expression can be sensitively detected using the newly synthesized multispectral fluorescence imaging probes Nimotuzumab-ICG and Atezolizumab-Cy5.5, which can facilitate the sensitive and specific detection of OSCC and improve treatment outcomes.

P3, N=416, Not yet recruiting, Sun Yat-sen University

P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=31, Recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital

P2, N=31, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital